The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry
Purpose The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast cancer, but can change during the disease course. This study aims to evaluate the biopsy rate and receptor subtype discordance rate in patients diagnosed with advanced breast cancer (ABC). Methods Patients diagnosed with ABC in seven hospitals in 2007–2018 were selected from the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry. Multivariable logistic regression analyses were performed to identify factors influencing biopsy and discordance rates. Results Overall, 60% of 2854 patients had a biopsy of a metastatic site at diagnosis. One of the factors associated with a reduced biopsy rate was the HR + /HER2 + primary tumor subtype (versus HR + /HER2- subtype: OR = 0.68; 95% CI: 0.51–0.90). Among the 748 patients with a biopsy of the primary tumor and a metastatic site, the overall receptor discordance rate was 18%. This was the highest for the HR + /HER2 + primary tumor subtype, with 55%. In 624 patients with metachronous metastases, the HR + /HER2 + subtype remained the only predictor significantly related to a higher discordance rate, irrespective of prior (neo-)adjuvant therapies (OR = 7.49; 95% CI: 3.69–15.20). Conclusion The HR + /HER2 + subtype has the highest discordance rate, but the lowest biopsy rate of all four receptor subtypes. Prior systemic therapy was not independently related to subtype discordance. This study highlights the importance of obtaining a biopsy of metastatic disease, especially in the HR + /HER2 + subtype to determine the most optimal treatment strategy..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:192 |
|---|---|
| Enthalten in: |
Breast cancer research and treatment - 192(2022), 2 vom: 13. Jan., Seite 331-342 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meegdes, Marissa [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Biopsy |
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s10549-021-06472-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078268305 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078268305 | ||
| 003 | DE-627 | ||
| 005 | 20230518174051.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10549-021-06472-5 |2 doi | |
| 035 | |a (DE-627)OLC2078268305 | ||
| 035 | |a (DE-He213)s10549-021-06472-5-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Meegdes, Marissa |e verfasserin |0 (orcid)0000-0002-7739-260X |4 aut | |
| 245 | 1 | 0 | |a The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Purpose The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast cancer, but can change during the disease course. This study aims to evaluate the biopsy rate and receptor subtype discordance rate in patients diagnosed with advanced breast cancer (ABC). Methods Patients diagnosed with ABC in seven hospitals in 2007–2018 were selected from the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry. Multivariable logistic regression analyses were performed to identify factors influencing biopsy and discordance rates. Results Overall, 60% of 2854 patients had a biopsy of a metastatic site at diagnosis. One of the factors associated with a reduced biopsy rate was the HR + /HER2 + primary tumor subtype (versus HR + /HER2- subtype: OR = 0.68; 95% CI: 0.51–0.90). Among the 748 patients with a biopsy of the primary tumor and a metastatic site, the overall receptor discordance rate was 18%. This was the highest for the HR + /HER2 + primary tumor subtype, with 55%. In 624 patients with metachronous metastases, the HR + /HER2 + subtype remained the only predictor significantly related to a higher discordance rate, irrespective of prior (neo-)adjuvant therapies (OR = 7.49; 95% CI: 3.69–15.20). Conclusion The HR + /HER2 + subtype has the highest discordance rate, but the lowest biopsy rate of all four receptor subtypes. Prior systemic therapy was not independently related to subtype discordance. This study highlights the importance of obtaining a biopsy of metastatic disease, especially in the HR + /HER2 + subtype to determine the most optimal treatment strategy. | ||
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Metastatic disease | |
| 650 | 4 | |a Hormone receptor | |
| 650 | 4 | |a HER2 receptor | |
| 650 | 4 | |a Subtype | |
| 650 | 4 | |a Biopsy | |
| 700 | 1 | |a Ibragimova, Khava I. E. |4 aut | |
| 700 | 1 | |a Lobbezoo, Dorien J. A. |4 aut | |
| 700 | 1 | |a Vriens, Ingeborg J. H. |4 aut | |
| 700 | 1 | |a Kooreman, Loes F. S. |4 aut | |
| 700 | 1 | |a Erdkamp, Frans L. G. |4 aut | |
| 700 | 1 | |a Dercksen, M. Wouter |4 aut | |
| 700 | 1 | |a Vriens, Birgit E. P. J. |4 aut | |
| 700 | 1 | |a Aaldering, Kirsten N. A. |4 aut | |
| 700 | 1 | |a Pepels, Manon J. A. E. |4 aut | |
| 700 | 1 | |a van de Winkel, Linda M. H. |4 aut | |
| 700 | 1 | |a Tol, Jolien |4 aut | |
| 700 | 1 | |a Heijns, Joan B. |4 aut | |
| 700 | 1 | |a van de Wouw, Agnes J. |4 aut | |
| 700 | 1 | |a Peters, Natascha A. J. B. |4 aut | |
| 700 | 1 | |a Hochstenbach-Waelen, Ananda |4 aut | |
| 700 | 1 | |a Smidt, Marjolein L. |4 aut | |
| 700 | 1 | |a Geurts, Sandra M. E. |4 aut | |
| 700 | 1 | |a Tjan-Heijnen, Vivianne C. G. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer research and treatment |d Springer US, 1981 |g 192(2022), 2 vom: 13. Jan., Seite 331-342 |w (DE-627)167913557 |w (DE-600)604563-7 |w (DE-576)01590217X |x 0167-6806 |7 nnns |
| 773 | 1 | 8 | |g volume:192 |g year:2022 |g number:2 |g day:13 |g month:01 |g pages:331-342 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10549-021-06472-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 192 |j 2022 |e 2 |b 13 |c 01 |h 331-342 | ||